Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 15/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.36 |
| ▸ | EPX | P11678 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297861 | 0.89 | MPO (0.50) | MPOLMNASMN1; SMN2 | |
| SCHEMBL19282247 | 0.88 | MPO (0.56) | MPOLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19282236 | 0.88 | KMT2A (0.51) | MPOMEN1KMT2ATPOEPX | |
| SCHEMBL19294233 | 0.87 | MPO (0.48) | MPOLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19282272 | 0.87 | MPO (0.68) | MPOLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19282211 | 0.86 | MPO (0.65) | MPO | |
| SCHEMBL17595126 | 0.85 | MPO (0.46) | MPOSMN1; SMN2TPOEPXALDH1A1 | |
| SCHEMBL19282316 | 0.84 | MPO (0.66) | MPOLMNAMEN1KMT2ATPO | |
| SCHEMBL19282300 | 0.81 | MPO (0.40) | MPOTPOEPX | |
| SCHEMBL19282354 | 0.81 | MPO (0.60) | MPOTPOEPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | claimed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | claimed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191486-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040419-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885LMNA 4800/4885SMN1; SMN2 4567/4885 |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885LMNA 4800/4885SMN1; SMN2 4567/4885 |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MPO 2/4885LMNA 4800/4885SMN1; SMN2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.